B‐cell haematological malignancies and SARS‐CoV‐2 infection: Could immunological interventions influence the outcome?

B cell haematological malignancies (HMs) have been described as the worst cancer type for concomitant COVID‐19 in terms of mortality, with rates up to 65%. This risk factor for COVID‐19 cannot only be explained by comorbidities and advanced age of patients, but aggravated by secondary immunodeficien...

Full description

Saved in:
Bibliographic Details
Published in:EJHaem 2021-08, Vol.2 (3), p.503-507
Main Authors: Ochoa‐Grullón, Juliana, Peña Cortijo, Ascensión, Guevara‐Hoyer, Kissy, Jiménez García, Carlos, Fuente, Eduardo, Peña, Antonia Rodríguez, Fernández‐Arquero, Miguel, González Fernández, Ata, Sánchez‐Ramón, Silvia
Format: Article
Language:English
Subjects:
Age
Antibodies
Asymptomatic
Coronaviruses
COVID-19
Disease prevention
Fever
Headaches
Hematology
Hospitals
Hypertension
Immune system
Immunodeficiency
Immunoglobulins
Immunology
Infections
Kidney diseases
Lymphoma
Morbidity
Mortality
Mucosa
Neutropenia
Pandemics
Patients
Pneumonia
Risk factors
Severe acute respiratory syndrome coronavirus 2
Short Report
Short Reports
Viral infections
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:B cell haematological malignancies (HMs) have been described as the worst cancer type for concomitant COVID‐19 in terms of mortality, with rates up to 65%. This risk factor for COVID‐19 cannot only be explained by comorbidities and advanced age of patients, but aggravated by secondary immunodeficiency (SID). We aimed at evaluating the impact of COVID‐19 on 86 HM patients with concomitant SID from a single centre. Only 14 HM patients of 86 (16.28%) patients suffered COVID‐19, with mortality rate of 7%. When we considered patients according to B‐cell defect only or multiple immune defect overlap (B‐T‐cell/NK cells/complement), patients with immune defect overlap presented 5.30‐fold higher risk of COVID‐19 than only B cell defect (95% CI, 1.67–17.0) (p = 0.004). Seven (50%) patients were on active IgRT; while five (36%) had received prior mucosal vaccines for respiratory infections. Our results show that modelling SID in HM may contribute to better prediction of infectious risk and to prompt more targeted and timely preventive therapies.
ISSN:2688-6146
2688-6146
DOI:10.1002/jha2.249